ArticleBMC gastroenterology2026
Correlation between liver fat fraction measured by MRI IDEAL-IQ sequence and ALT, GGT, and AST in colorectal cancer patients after chemotherapy.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe aim of our study was to evaluate the correlation between hepatic fat fraction (HFF) and ALT, GGT, and AST in patients with colorectal cancer after FOLFOX4 chemotherapy.
methodsThis retrospective study included 56 colorectal cancer patients who received FOLFOX4 chemotherapy and 60 non-chemotherapy patients as controls. HFF was quantified from MRI-PDFF images by placing regions of interest in eight Couinaud liver segments. Liver enzyme levels (ALT, GGT, AST) were measured from fasting blood samples. Interobserver consistency for HFF measurements was evaluated using intra-class correlation coefficient (ICC). The normality of data was assessed using the D’Agostino–Pearson test. Spearman correlation and multiple linear regression (adjusted for age, BMI, diabetes, and hypertension) were used to analyze associations between HFF and liver enzymes. Diagnostic performance of HFF was evaluated using receiver operating characteristic (ROC) curve analysis.
resultsInterobserver agreement for HFF measurements was excellent (ICC = 0.892). In the chemotherapy group, HFF showed a strong positive correlation with GGT (r = 0.838, p < 0.001) and AST (r = 0.518, p < 0.001). After adjustment for confounders, HFF remained independently associated with ALT (β = 1.026, p = 0.029), GGT (β = 13.078, p < 0.001), and AST (β = 1.227, p = 0.007). ROC analysis indicated that HFF effectively predicted elevated liver enzymes: for GGT, AUC = 0.942 (cut-off: 12.275%, sensitivity 92.3%, specificity 83.3%); for AST, AUC = 0.817 (cut-off: 13.15%, sensitivity 90.0%, specificity 67.4%); for ALT, AUC = 0.789 (cut-off: 12.95%, sensitivity 90.9%, specificity 64.4%).
conclusionOur results suggest that HFF is correlated with ALT / GGT and AST levels in colorectal cancer patients treated with FOLFOX4 chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.